Cargando…
ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence
In this review, we undertake a critical appraisal of eight published studies providing first evidence that a history of attention-deficit/hyperactivity disorder (ADHD) may increase risk for the later-life development of a neurodegenerative disease, in particular Lewy body diseases (LBD), by up to fi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822599/ https://www.ncbi.nlm.nih.gov/pubmed/35145394 http://dx.doi.org/10.3389/fnagi.2021.826213 |
_version_ | 1784646630262177792 |
---|---|
author | Becker, Sara Sharma, Manu J. Callahan, Brandy L. |
author_facet | Becker, Sara Sharma, Manu J. Callahan, Brandy L. |
author_sort | Becker, Sara |
collection | PubMed |
description | In this review, we undertake a critical appraisal of eight published studies providing first evidence that a history of attention-deficit/hyperactivity disorder (ADHD) may increase risk for the later-life development of a neurodegenerative disease, in particular Lewy body diseases (LBD), by up to five-fold. Most of these studies have used data linked to health records in large population registers and include impressive sample sizes and adequate follow-up periods. We identify a number of methodological limitations as well, including potential diagnostic inaccuracies arising from the use of electronic health records, biases in the measurement of ADHD status and symptoms, and concerns surrounding the representativeness of ADHD and LBD cohorts. Consequently, previously reported risk associations may have been underestimated due to the high likelihood of potentially missed ADHD cases in groups used as “controls”, or alternatively previous estimates may be inflated due to the inclusion of confounding comorbidities or non-ADHD cases within “exposed” groups that may have better accounted for dementia risk. Prospective longitudinal studies involving well-characterized cases and controls are recommended to provide some reassurance about the validity of neurodegenerative risk estimates in ADHD. |
format | Online Article Text |
id | pubmed-8822599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88225992022-02-09 ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence Becker, Sara Sharma, Manu J. Callahan, Brandy L. Front Aging Neurosci Aging Neuroscience In this review, we undertake a critical appraisal of eight published studies providing first evidence that a history of attention-deficit/hyperactivity disorder (ADHD) may increase risk for the later-life development of a neurodegenerative disease, in particular Lewy body diseases (LBD), by up to five-fold. Most of these studies have used data linked to health records in large population registers and include impressive sample sizes and adequate follow-up periods. We identify a number of methodological limitations as well, including potential diagnostic inaccuracies arising from the use of electronic health records, biases in the measurement of ADHD status and symptoms, and concerns surrounding the representativeness of ADHD and LBD cohorts. Consequently, previously reported risk associations may have been underestimated due to the high likelihood of potentially missed ADHD cases in groups used as “controls”, or alternatively previous estimates may be inflated due to the inclusion of confounding comorbidities or non-ADHD cases within “exposed” groups that may have better accounted for dementia risk. Prospective longitudinal studies involving well-characterized cases and controls are recommended to provide some reassurance about the validity of neurodegenerative risk estimates in ADHD. Frontiers Media S.A. 2022-01-25 /pmc/articles/PMC8822599/ /pubmed/35145394 http://dx.doi.org/10.3389/fnagi.2021.826213 Text en Copyright © 2022 Becker, Sharma and Callahan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Aging Neuroscience Becker, Sara Sharma, Manu J. Callahan, Brandy L. ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence |
title | ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence |
title_full | ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence |
title_fullStr | ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence |
title_full_unstemmed | ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence |
title_short | ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence |
title_sort | adhd and neurodegenerative disease risk: a critical examination of the evidence |
topic | Aging Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822599/ https://www.ncbi.nlm.nih.gov/pubmed/35145394 http://dx.doi.org/10.3389/fnagi.2021.826213 |
work_keys_str_mv | AT beckersara adhdandneurodegenerativediseaseriskacriticalexaminationoftheevidence AT sharmamanuj adhdandneurodegenerativediseaseriskacriticalexaminationoftheevidence AT callahanbrandyl adhdandneurodegenerativediseaseriskacriticalexaminationoftheevidence |